The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.

In what seems a significant step forward in pain management, the US Food and Drug Administration has approved a new non-opioid painkiller for treating short-term pain in adults. Veuer’s Maria Mercedes ...

A Nigerian man has been extradited to the US to face charges in the “sextortion” of a South Carolina teen who died by suicide in 2022. Prosecutors allege the scammer posed as a young woman, persuaded ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioi ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX stock over the recent years has been far from consistent, and has largely ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Discover the latest trends in the business world, from Barnes and Noble's growth fueled by BookTok to the FDA's approval of a new nonopioid pain medication.

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.